The expansion of kinase assay technologies over the past decade has mirrored the growing interest in kinases as drug targets. As a result, there is no shortage of convenient, fluorescence-based methods available to assay targets that span the kinome. The authors recently reported on the development of a non-activity-based assay to characterize kinase inhibitors that depended on displacement of an Alexa Fluor  647 conjugate of staurosporine (a "tracer") from a particular kinase. Kinase inhibitors were characterized by a change in fluorescence lifetime of the tracer when it was bound to a kinase relative to when it was displaced by an inhibitor. Here, the authors report on improvements to this strategy by reconfiguring the assay in a time-resolved fluorescence resonance energy transfer (TR-FRET) format that simplifies instrumentation requirements and allows for the use of a substantially lower concentration of kinase than was required in the fluorescence-lifetime-based format. The authors use this new assay to demonstrate several aspects of the binding assay format that are advantageous relative to traditional activity-based assays. The TR-FRET binding format facilitates the assay of compounds against lowactivity kinases, allows for the characterization of type II kinase inhibitors either using nonactivated kinases or by monitoring compound potency over time, and ensures that the signal being detected is specific to the kinase of interest and not a contaminating kinase. (Journal of Biomolecular Screening 2009:924-935) 
INTRODUCTION
A ctivity-based kinase assays in a variety of fluorescent assay formats have become routine and have largely replaced radioactivity as a means for characterizing recombinant kinases in many applications. Common requirements for all activity-based assays include a suitable substrate for phosphorylation, sufficient catalytic activity to generate an adequate amount of product for detection, and a direct or indirect means of detecting the phosphorylation event. There are exceptions to these requirements, such as the use of nonactivated kinases in "cascade" types of assays 1 or the use of water as a nonspecific phosphoacceptor substrate, 2 but these exceptions often come with their own caveats such as complications from nonlinear product formation or slower reaction rates. In contrast, the requirements for an assay to directly measure the affinity of a compound for a kinase are much less demanding.
Such assays do not require adenosine triphosphate (ATP) or phosphoacceptor substrate or a means of detecting either substrate consumption or corresponding product formation. In addition, the rate of catalytic efficiency (kinase activity) does not have any direct bearing on the assay.
Direct binding of an inhibitor to the ATP binding site of a kinase domain has been measured by monitoring changes in the intrinsic fluorescence of aromatic residues in the kinase, 3 but neither the breadth of kinases to which this technique can be applied nor the suitability for use in a low-volume, highthroughput format has been shown. A potentially more broadly applicable approach is based on the ability of a compound to compete with a fluorescent, ATP site-directed probe (tracer) for binding to a kinase and detecting the binding (or displacement) of that tracer by a change in the fluorescent properties of the system. Such a strategy was employed more than 2 decades ago by the Leonard lab, which used fluorescence polarization (FP) to characterize the affinities of different nucleotides for a kinase, by monitoring the polarization of an adenosine diphosphate (ADP)-derived tracer. 4 By using other ATP site-directed tracers based on broadspectrum, high-affinity kinase inhibitors, we 5 and others [6] [7] [8] [9] have developed assay platforms designed to characterize kinase inhibitors based on this competitive binding principle and that are intended to cover a broad portion of the kinome.
Despite the utility of these platforms, the assay readouts reported for these methods include fluorescence lifetime (FLT), qPCR (using kinases that are expressed as fusions to T7 bacteriophage), mass spectrometry, or an enzyme-fragment complementation (EFC) detection format, all of which compromise the utility of the assay for many applications. The FLT-based assay is the only one of the 4 that have been described that is a single-step, homogeneous, "mix-and-read" format (kinase, compound, and tracer are the only assay components present), but instruments capable of performing FLT-based assays are expensive and not commonly available. For the other assay formats that have been described, significant manipulations following addition of compound and tracer to the kinase are required, and aside from the EFC approach, the readouts are difficult to perform in a nonspecialist laboratory. Homogeneous probe displacement assays using the more common readouts of fluorescence intensity, 10 FP, 2 or time-resolved fluorescence resonance energy transfer (TR-FRET) 11 have been described but with more specific probes that limit the range of kinases that can be addressed.
Here, we report on improvements to our previously described, FLT-based kinase binding assay format 5 that have been made by developing a similar assay in a TR-FRET format (Fig. 1) . The previously described FLT-based assay depended on a fluorescence lifetime change that could be observed when a tracer consisting of an Alexa Fluor  647 conjugate of staurosporine was displaced from a kinase by an active site-directed kinase inhibitor. For a large number of kinases tested, binding of the tracer to the kinase increased the fluorescence lifetime of the Alexa Fluor  647 moiety, and a dose-dependent change in tracer lifetime due to displacement of the tracer with a set of known kinase inhibitors correlated well with traditional activitybased measurements. However, one limitation of the format was revealed with a kinase that had a low affinity for the tracer, in that (similar to a FP assay) 12 the observed IC 50 values for a set of potent compounds were "right shifted" in the FLT assay due to the high concentration of kinase required (relative to the amount required for an activity assay). By reconfiguring the assay in a TR-FRET format, the lower limit of resolvable compound potencies is reduced because in this format, the FIG. 1. Schematic of the LanthaScreen  Eu-based time-resolved fluorescence resonance energy transfer (TR-FRET)-based kinase binding assay. An epitope-tagged recombinant kinase is incubated with a europium-labeled, antitag antibody, an Alexa Fluor  647-labeled tracer that is capable of binding to the adenosine triphosphate (ATP) binding site of the kinase, and test compound. If the test compound does not bind to the kinase, TR-FRET is detected between the antibody and the Alexa Fluor  647 fluorophore that is incorporated into the tracer. If the compound binds to the ATP binding site of the kinase, the tracer is displaced in a dose-dependent manner by the compound, resulting in a decrease in the TR-FRET signal. kinase can be present at a concentration below the kinase⋅tracer K d value while maintaining a robust signal. 13 In addition, the change in fluorescence lifetime in the previously reported assay was a "fortuitous" event, and because it is difficult to predict or design probes that will undergo a change in fluorescence lifetime upon binding to a receptor, the TR-FRET format allows for a more rational and predictable approach to be taken toward assay development.
MATERIALS AND METHODS
Unless otherwise stated, all kinases, tracers, and antibodies used in this study were from Invitrogen (Madison, WI). Kinase inhibitors were from Calbiochem (San Diego, CA), American Custom Chemicals Corporation (San Diego, CA), Tocris (Ellisville, MO), Axxora (San Diego, CA), or Invitrogen. Curve fitting and data analysis were performed with GraphPad Prism software (GraphPad Software, Inc., La Jolla, CA). Binding and activity assays were performed in 384-well lowvolume plates (Corning part #3676, Corning, NY) at room temperature in Kinase Buffer A (Invitrogen PV3189), which consists of 50 mM HEPES (pH 7.5), 0.01% BRIJ-35, 10 mM MgCl 2 , and 1 mM EGTA. TR-FRET activity assays were performed using the LanthaScreen  activity assay format essentially as described previously. 14 For all experiments with a kinase inhibitor, a dilution series of inhibitor was first prepared in 100% DMSO at 100-fold the desired final assay concentration. From this master dilution series, inhibitors were diluted 33.3-fold into Kinase Buffer A, for an intermediate concentration of inhibitor that was 3-fold of that to be used in the assay, in 3% DMSO. To 5 µL of each concentration of inhibitor to be tested, appropriate assay reagents were added (as described below for individual experiments) to bring the final volume to 15 µL and the final DMSO concentration to 1%. In general, all assays were performed with 3 replicates of each inhibitor concentration.
Assay plates were read using either a Tecan Infinite F500 or BMG PheraStar using standard Eu-based TR-FRET settings with excitation at 340 nm and emission monitored at 615 nm (donor) and 665 nm (acceptor). Emission intensities were measured over a 200-µs window following a 100-µs postexcitation delay. Data are presented either as a ratio of raw acceptor/donor intensities or normalized relative to wells containing fully bound or fully competed tracer (relative percent tracer bound).
Measurement of inhibitor binding to active or nonactive Abl
The activated Abl used was full-length, his-tagged human recombinant protein expressed in insect cells. Nonactivated Abl was prepared by treating activated Abl with YOP protein tyrosine phosphatase (YOP PTP, New England Biolabs, Ipswich, MA) essentially as described previously. 15 Briefly, a 50-µL, 640-nM solution of Abl in 1× NEBuffer for Protein Tyrosine Phosphatases (50 mM Tris-HCl, 100 mM NaCl, 2 mM Na 2 EDTA, 5 mM dithiothreitol [DTT], 0.01% Brij 35, pH 7.5) containing 25 units of YOP was incubated at 30°C for 30 min, placed on ice, and then used immediately. Binding assays for either activated or nonactivated Abl contained 1 nM kinase, 2 nM Eu-anti his-tag antibody, and 0.25 nM Kinase Tracer 178. The data reported are the averages of 3 independent experiments.
Measurement of inhibitor binding to p38 and BRAF
Full-length, glutathione-S-transferase (GST)-tagged, p38α (MAPK14) was used, which had been expressed in Escherichia coli and activated in vitro by MAP2K6. Kinase and Eu-anti-GST-tag antibody were each present at 1 nM, and 30 nM Kinase Tracer 199 was used. BRAF assays were conducted using 5 nM full-length, GST-tagged BRAF, 2 nM Eu-anti-GST antibody, and 20 nM Kinase Tracer 178. For both assays, 5 µL of tracer was first added to 5 µL of inhibitor, and then 5 µL of a solution containing both antibody and kinase was added. Assay plates were read at various time points and the data from each time point normalized relative to assay wells at that time point that contained either noncompeted or fully competed tracer. BRAF activity assays were performed as described previously 1 with all reagents except ATP first combined before adding ATP to initiate the reaction at the specified time point.
Measurement of inhibitor binding to cyclin-dependent kinases (CDKs)
The CDK5/p25 complex contained full-length, his-tagged CDK5 and full-length GST-tagged p25. CDK7/cyclin H/MNAT1, CDK8/cyclin C, CDK9/cyclin K, and CDK9/cyclin T contained full-length, his-tagged subunits. All assays contained 1 nM kinase and 1 nM Eu-labeled antibody, except the CDK9/cyclin K assay, which contained 2 nM antibody. The CDK5/p25 assay used a Eu-anti his-tag antibody, whereas all other assays used a Eu-anti GST antibody. CDK5/p25, CDK7/cyclin H/MNAT1, and CDK9/cyclin K assays contained 100 nM Kinase Tracer 236, and CDK8/cyclin C and CDK9/cyclin T assays contained 25 and 50 nM Kinase Tracer 236, respectively. The assay plates were read 1 h after all reagents were added. The data reported are the averages of 3 independent experiments. K i values were determined using the Cheng-Prusoff equation, 16 
Assay of inhibitor binding to epidermal growth factor receptor in the presence of crude cellular lysate
Soluble cell extracts from HeLa S3 cells (ATCC CCL-2.2) were prepared by dounce homogenization in homogenization buffer (10 mM HEPES [pH 7.5], 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM DTT, 1 mM PMSF, 1 µg/mL leupeptin, 1 µg/mL pepstatin A, 5 mM benzamidine, 10 µM E-64, and 20 µg/mL aprotinin) using cells previously washed 2 times with Trisbuffered saline (TBS; 50 mM Tris-HCl, 150 mM NaCl, pH 7.5) and then once with the homogenization buffer. After homogenization, the extract was centrifuged for 7 min at 1000g. Lysates were frozen and stored at -80°C. Binding assays were performed with 2.5 nM epidermal growth factor receptor (EGFR; amino acids 668-1210 expressed as a GST-fusion protein), 2 nM Eu-anti GST, and 70 nM Kinase Tracer 236 in Kinase Buffer A in 16-µL assays. Activity assays were performed with 0.5 nM EGFR and 3 µM ATP with 200 nM Fluorescein Poly GT substrate in Kinase Buffer A. For both assay formats, lysate was added to a final concentration of 300 µg/mL. Inhibitors were prepared as described above but were prepared as 4-fold stocks by 1:25 dilution into Kinase Buffer A. Activity assays were started by the addition of ATP and were allowed to proceed for 1 h at room temperature. Activity assays were stopped by adding 10 mM EDTA and phosphorylation of the substrate detected by the addition of 2 nM Tb-PY20 antibody as previously described. 14 
RESULTS AND DISCUSSION

General considerations in the development of suitable tracers
In our previously reported assay that depended on a change in fluorescence lifetime to indicate displacement of the tracer from a kinase, 5 the tracer we used (an Alexa Fluor  647 conjugate of staurosporine) was fortuitously found to have the property of exhibiting a change in fluorescence lifetime when bound to a wide range of kinases. The molecule we used as a tracer in those studies had in fact been designed for other experiments, for which it was found to be unsuitable because of this property.
For the 3 tracers used in the current study, a similar approach was taken in that broad-spectrum kinase inhibitors were derivatized to require the preparation of only a limited set of tracers that would address as wide a range of kinases as possible. In the course of developing these tracers, several points were considered and were found to be critical to the successful development of the tracer molecules. The first consideration was the point of conjugation to the small-molecule inhibitor. As noted in our previous work, staurosporine conjugates had been previously described that maintained affinity for a range of kinases, and the point of attachment of the conjugate to the staurosporine corresponded to a particular nitrogen atom that is shown to be solvent exposed in a number of crystal structures.
A second and perhaps less obvious consideration in the development of this assay platform was the method for attachment of the fluorescent molecule to the inhibitor. With respect to optimization of the 3 tracers developed for the TR-FRET format reported here, we prepared approximately 50 different analogs based off of 3 different kinase inhibitor scaffolds, consisting of different linkage chemistries, different linker lengths, and different acceptor dyes, and then tested each candidate tracer against a panel of kinases to find the most optimal tracer molecule based on a particular core scaffold (data not shown). We found that although a suitable point of attachment of the dye to the small-molecule inhibitor can often be rationalized based on previously published studies involving the inhibitor, determination of the optimal linkage chemistry between the inhibitor and the dye to optimize both affinity and assay window is a largely empirical process. To a large extent, assay window and tracer affinity are linked properties-when a lowaffinity tracer is used, a higher concentration of tracer is required to bind to the kinase to provide a suitable assay window between bound and displaced tracer. However, at high concentrations of tracer, the extent of background (diffusionenhanced) 17 FRET rises, narrowing this assay window. As a practical "upper limit," we found that tracers for which the kinase⋅tracer K d value was < ~400 nM, a suitable assay (Z′ > 0.5) could be developed using 100-nM tracer.
Characterization of inhibitor potency against activated and nonactivated Abl
We tested the ability of the kinase binding assay to characterize inhibitor potency against active and nonactivated forms of a kinase using Abl. Abl is involved in a number of cancers, and an inhibitor of Abl, imatinib (Gleevec  , STI-571), was the first ATP site-directed small-molecule kinase inhibitor to be approved by the Food and Drug Administration (FDA). Consequently, the inhibition of Abl by imatinib has been studied extensively, both biochemically and by crystallography. 15, 18 These studies revealed that imatinib binds to Abl as a "type II" inhibitor, 19 binding to both the ATP binding pocket as well as to an adjacent "allosteric pocket" that is formed when a highly conserved DFG-motif is flipped to an "out" position, which in many kinases is favored by the nonactivated (nonphosphorylated) form of the kinase. Imatinib has been shown to bind substantially tighter to the nonactivated form of Abl, relative to its affinity for the active form of the kinase. 15, 18 We tested 6 inhibitors for their ability to displace tracer from either active or nonactive Abl, with the results shown in Figure 2 and tabulated in Table 1 . Three of the inhibitors tested-staurosporine, sunitinib (Sutent  , SU-11248), and VX-680-showed negligible differences in affinity for either the active or nonactive form of the kinase, presumably because the conformation of the DFG loop that varies between active and nonactive Abl does not affect the ability of these inhibitors to bind to the kinase. In contrast, imatinib showed the expected shift in potency, binding to the nonactivated form of the kinase with approximately 16-fold higher affinity. Interestingly, 2 other inhibitors, BIRB 796 and sorafenib (Nexavar  , BAY 43-9006), both of which have been shown to bind as type II inhibitors to other kinases (p38 and BRAF, respectively), 10, 20 showed a similar effect. Both inhibitors were relatively weak but were observed to bind to the nonactivated form of Abl with more than 10-fold greater affinity than the activated form of the kinase.
Characterization of slow-binding inhibitors to p38 and BRAF
In addition to showing preferential binding to the nonactivated form of a kinase, another property that has been demonstrated for many type II kinase inhibitors is "slow-binding" kinetics. This property has been most extensively studied for BIRB 796, which binds to both active and nonactive forms of p38α, β, γ, and δ, 10,21 and this slow binding has been extensively demonstrated in both activity-based assays 10, 21, 22 as well as in experiments designed to directly measure compound binding. 10, 23, 24 We were able to reproduce these results in our TR-FRET-based format and observed a shift in the IC 50 of BIRB 796-dependent tracer displacement from approximately 1 µM to 20 nM over the course of 6 h (Fig. 3) . Over the same time period, the classical ATP site-directed p38 inhibitor, SB202190, showed no shift in IC 50 , which was observed to be approximately 20 nM and is again similar to that described previously. 22 To test the ability of the kinase binding assay to characterize other type II inhibitors in this manner, we examined the ability of GW5074, sorafenib, and ZM336372 to bind to BRAF over time ( Fig. 4) . GW5074 is a benzylidine oxindole derivative that has been shown to inhibit RAF family kinases, 25 but neither it nor structurally similar molecules have been shown to bind to BRAF or other kinases as type II inhibitors. 26 Sorafenib, an approved compound for the treatment of hepatocellular carcinoma, has been demonstrated by crystallography to bind as a type II inhibitor, 20 and the third compound, ZM336372, has also been described as a type II inhibitor of RAF kinases. 27, 28 However, unlike the example of BIRB 796 binding to p38 kinases, to our knowledge, the time dependence of potency for either compound binding or kinase inhibition has not been demonstrated in vitro for these molecules. In our experiments, GW5047 demonstrated a constant level of tracer displacement or inhibition of kinase activity over the course of 4 h. In the activity assay, there was a negligible shift in potency (from an IC 50 of 22 nM to 15 nM) when the compound was preincubated with kinase for either 15 min or 30 min prior to initiating the reaction, and then the IC 50 was essentially constant throughout 4 h. In the binding assay, the IC 50 was constant at 3.8 ± 0.4 nM over the course of the experiment. Sorafenib showed the largest increase in potency over the timeframe of the assay, with a binding assay IC 50 that decreased approximately 10-fold between 10 min and 4 h (from 1.2 µM to 120 nM) and an activity assay IC 50 that decreased 5-fold, from 600 nM to 130 nM, over a similar timeframe. Finally, ZM336372 displayed a 4-fold decrease in IC 50 in the binding assay, from 211 nM to 53 nM, and a smaller change (from 430 nM to 190 nM) in the activity assay.
In each of the examples shown here, the assay window was stable over the course of several hours, and in fact the assay plates could be read after an overnight incubation, with minimal impact on assay window. However, with other kinases, the assay window could be seen to decrease over the course of an overnight incubation (data not shown), likely due to a lack of stability of the individual kinase. However, because in general the assay is configured such that the kinase is present at a concentration below the K d for the kinase⋅tracer interaction, a decrease in the concentration of properly folded kinase present (that is able to bind tracer) is expected to affect only the assay window and not the observed IC 50 value of a compound in the assay.
Characterization of compounds that bind to CDKs
Cyclin-dependent kinases (CDKs) are of interest as therapeutic targets for oncology and other indications and are involved in regulated progression through the cell cycle. 29 Recently, the CDK family member CDK8 has been shown to be a colorectal cancer oncogene. 30, 31 When we expressed and purified a recombinant human CDK8/cyclin C complex from insect cells using full-length, his-tagged fusion proteins, the purified complex exhibited negligible activity (0.3 nmol of phosphate transferred/ [min⋅mg kinase]) in a radiometric assay against a peptide derived from the C-terminus of RNA polymerase-II (a physiologically relevant substrate) and lower to undetectable activity when tested against other common serine/threonine kinase substrates. Based on pervious experience with kinases of similarly low levels of activity, we expected it would be difficult to develop an activity-based assay to characterize CDK8 inhibitors.
In the absence of an activity-based assay for CDK8 inhibitors, we tested the ability of 6 inhibitors to displace tracer from CDK8, with the results shown in Figure 5 . Roscovitine and CDK9 Inhibitor II (4-(3,5-diamino-1H-pyrazol-4-ylazo)-phenol) inhibited tracer binding weakly, with K i values >10 µM. CDK/CRK inhibitor (RGB-286147) inhibited with a K i near 120 nM, which is within the range of IC 50 values seen for a variety of CDKs with this inhibitor, 32 and CDK2/9 inhibitor ((4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2yl)-(3-nitrophenyl)amine) demonstrated a K i of 72 nM, also within the range of potencies seen for this inhibitor with other CDKs. 33 The adenosine mimetic 5-iodotubercidin and the broad-spectrum kinase inhi bitor staurosporine bound tightest, with K i values of 23 nM and 2.8 nM, respectively.
Because it has been identified as an oncogene only recently (and perhaps due to its low activity), there is a lack of data in the literature for small-molecule inhibitors of CDK8. In a recent report that tested the affinity of a panel of inhibitors against phage-displayed (noncomplexed) CDKs, staurosporine was reported to inhibit CDK8 with a K i of 510 nM, 34 substantially higher than the 2.8 nM we observed. Because of the importance of CDK8 as an oncology target, we explored this Table 2 . In all cases tested, staurosporine bound from 3-to 240-fold more tightly to the complexed CDK relative to the noncomplexed, phage-displayed kinase, and in general, there was poor correlation of data for all inhibitors tested between the complexed CDKs tested here and the noncomplexed CDKs reported previously. 34 For example, sunitinib was seen to inhibit tracer binding with a K i <1 µM for all of the complexed CDKs, in contrast to >10 µM reported for 4 of the 5 the noncomplexed CDKs. When we separately tested staurosporine as an inhibitor for CDK5/p25, CDK7/cyclin H/MNAT1, or CDK9/cyclin T1 in an ADP detection-based activity assay, IC 50 values of 3.7 nM, 29 nM, and 5.7 nM, respectively, were obtained (data not shown), similar to the K i values obtained in the binding assay using complexed CDKs. Because our CDK8 results show potent inhibition by other reported CDK inhibitors, and because our staurosporine-based data for other CDKs correlate with that seen in activity-based assays, we conclude that noncomplexed CDKs are a poor surrogate for complexed CDKs when characterizing compounds for their ability to bind to or inhibit CDK activity. However, it is possible that the discrepancies in our inhibitor results from those previously reported, as well as the low activity of the kinase itself, are a result of improperly folded kinase.
Characterization of compound potency in the presence of contaminating kinases
As new kinases are identified as therapeutic targets, there is often a paucity of information available on physiologically relevant substrates, which can lead to difficulty in designing a suitable assay. When assaying tyrosine kinases, random copolymers of glutamate and tyrosine (E4Y) are often used as "generic" substrates, and in our experience, nearly all tyrosine kinases show detectable levels of activity against this substrate. For serine/ threonine kinases, no such "generic" substrate exists, although many serine/threonine kinases will phosphorylate myelin basic protein (MBP). A broadly applicable assay strategy for serine/ threonine kinases has been reported that uses a set of 3 peptides that contain motifs that are phosphorylated by a broad range of serine/threonine kinases, and by using a single antibody that recognizes the phosphorylated form of any of these peptides, assays can be developed readily. 35 However, with any of these strategies, there is a danger of measuring a contaminating kinase rather than the kinase of interest, especially given that the substrates used are designed to be phosphorylated by a broad spectrum of kinases. Because the kinase binding assay format only measures binding to a specific, "tagged" kinase (which is recombinantly expressed and therefore is the only protein present that contains the tag), the measured assay signal is specific to the kinase of interest and therefore should not be affected by the presence of other kinases.
To demonstrate the resistance of the kinase binding assay to erroneous results due to contaminating kinases, we performed traditional activity inhibition assays, or kinase binding assays, in the absence or presence of a high concentration (300 µg/mL) of crude HeLa cellular lysate. A tyrosine kinase, EGFR (ErbB1), was chosen, with the intention that in the activity assay (using a labeled E4Y substrate), detection of inhibition of EGFR by specific EGFR inhibitors such as erlotinib (Tarceva  ) or gefitinib (Iressa  ) 36 would be "masked" due to phosphorylation of the substrate by endogenous kinases in the lysate. As expected, in the absence of cellular lysate, these compounds demonstrated potent, sub-nanomolar inhibition of EGFR or competition for the tracer in both assay formats (Fig. 6A, B) . Staurosporine and SB203590 also inhibited the activity measurements and competed for binding of the tracer (IC 50 values of 50 and 38 nM for staurosporine and 350 and 250 nM for SB203590 in the activity and binding assays, respectively). In contrast, in the presence of cellular lysate, both erlotinib and gefitinib failed to potently inhibit the activity assay, only inhibiting 50% of the activity at the 10-µM compound, whereas the binding assay still demonstrated sub-nanomolar inhibition for these compounds in the presence of lysate (Fig. 6C, D) . SB203590 inhibition was also dramatically affected by the addition of cellular lysate in the activity assay, with a maximum inhibition of 40% at the 10-µM compound, whereas the binding assay IC 50 values remained similar in the absence or presence of the lysate. Staurosporine, a broad-spectrum kinase inhibitor, still exhibited inhibition of the activity assay, likely due to its ability to inhibit the activity of the contaminating tyrosine kinases present in the cellular lysate. These data exemplify the advantages of the binding assay when working with kinase preparations that might contain highly active contaminating kinases: because the epitope tag is present only on the recombinant enzyme, the signal measured in the binding assay is specific to the kinase that contains that tag, and contaminating kinases do not interfere in the assay.
CONCLUSIONS
In this report, we have demonstrated the utility of a TR-FRET-based kinase binding assay for the characterization of inhibitors binding to either active or nonactivated kinases. This assay format results in a highly specific signal for the kinase of interest, yielding reliable data even in the presence of added phosphatase or crude cellular lysates. Perhaps more important, this simple assay format enables facile detection and characterization of type II kinase inhibitors by 2 methods. First, compounds with a slow-binding mechanism, which is frequently observed for type II inhibitors, can be readily identified by simply measuring binding reactions at various time points, as demonstrated for p38α and BRAF. Second, unlike activity assays, this assay enables facile characterization of nonactivated kinase preparations, as demonstrated by the tighter binding observed for 3 type II inhibitors (but not type I inhibitors) to dephosphorylated Abl compared to the activated (phosphorylated) kinase. In this manner, compounds that preferentially bind to nonactivated forms of a kinase can be readily identified and studied. Although not shown in this work, we have begun to explore the ability of this assay format to monitor compound off-rates by premixing kinase, compound, and antibody and then diluting the resulting complex into a solution of excess tracer. In this format, the individual assay wells are then monitored in real time as the compound dissociates from the kinase and is replaced by tracer. A more extensive exploration of this application is ongoing in our lab.
An important consideration of any assay-especially a biochemical kinase assay, for which the available options are numerous-is a comparison of the strengths and weaknesses of that format relative to other available formats. In addition to the strengths highlighted above, the amount of kinase needed in this particular assay can be compared and contrasted to that required in other formats. In general, the amount of kinase required in the TR-FRET format that we have described ranges between approximately several hundred picomolar and several nanomolar. In comparison to activity-based assays-especially in TR-FRET-based activity assays, in which full assay signal is achieved upon saturating nanomolar amounts of a labeled phosphospecific antibody with appropriately labeled phosphorylated substrate-the amount of kinase required in the assay reported here can be substantially higher. However, for lower activity kinases, the binding assay presented here may be advantageous in terms of the amount of kinase required.
In our previously reported fluorescence lifetime-based binding assay, the kinase concentration was required to be greater than or equal to the K d value for the kinase⋅tracer interaction, and this property negatively affected the ability of the assay to properly resolve tight binding inhibitors from one another because the observed potency was limited by the high amount of kinase present in the assay. 5 For example, in that format, 70 nM PCK-theta (PRKCQ) kinase was required to bind to a sufficient fraction of its tracer to develop a suitable assay, and this negatively affected the ability of the assay to properly report affinities of tight binding inhibitors. For example, the tight binding inhibitor, staurosporine, was seen to compete with tracer with an IC 50 of 40 nM, which was approximately 10-fold higher than that seen when tested in 2 different activity assays that used substantially lower concentrations of kinase. When the same assay was reconfigured in the TR-FRET format presented here, the observed IC 50 for staurosporine was reduced to 3 nM (data not shown). 37 The ability to use a sub-K d concentration of kinase, as well as a concentration of tracer that is close to the K d for the kinase⋅tracer interaction, is particularly advantageous when using tracers that have relatively low affinity for the kinase (>100 nM K d ) and is a distinguishing feature of the TR-FRET format that we have presented when compared to binding assays performed in FLT, 5 FP, 2 or EFC 7 formats.
Although the convenience of using an epitope tag for the purification or visualization of a recombinant kinase is well established, such tags could potentially alter the activity of the kinase being studied. Preliminary data suggest that the method presented here could be extended to the use of native or untagged kinases by indirectly labeling the kinase of interest with a europium-labeled antibody that is specific to a unique sequence within the kinase of interest. However, because the use of GST-or his-tagged kinases allows for the convenience of developing a limited set of common reagents to address a large range of kinases, we have focused our efforts on these. Over the course of developing this assay platform, no obvious difference in assay performance was observed for the location of the tag (C-or N-terminus), but in general larger assay windows were often observed for GST-tagged (rather than His-tagged) kinases.
The readout format we have employed for this assay, TR-FRET, was specifically chosen due to its resistance to many common types of interference that can be encountered in an HTS setting. The assay readout depends on the use of a longlifetime, europium-based donor fluorophore, which allows FRET to be measured after a brief postexcitation (~100-µs) delay. By incorporating this delay before measuring the assay signal, prompt fluorescence due to direct excitation of autofluorescent library compounds or scattered light from precipitated compounds is not measured and does not interfere with the assay. To further increase data quality, the FRET signal is expressed as a ratio of the acceptor signal relative to the donor signal. 38, 39 Although these features lead to the resistance to many types of assay interference, high concentrations of autofluorescent compounds can still serve as FRET acceptors via a nonspecific diffusion-enhanced FRET mechanism, and compounds that cause aggregation of assay components can interfere as well. Although TR-FRET-based kinase assays are often thought of as being expensive, this is largely due to the expense associated with quality phosphospecific antibodies (as well as the expense involved in screening candidate phosphospecific antibodies to determine a clone with optimal performance in that particular application). By using more "generic" antibodies in the binding assay format, some of the costs associated with phosphospecific antibodies can be avoided. It should be noted, however, that multiple sources and preparations of anti-his and anti-GST antibodies were evaluated in the course of developing this platform, and substantial differences in performance were noted between different antibody sources.
As a final point of awareness (and as we have demonstrated in this report), differences in inhibitor potency may be observed for some inhibitors depending on the activation (phosphorylation) state of the kinase being investigated. When preparing recombinant kinases, variations in phosphorylation state between different preparations of a given kinase could contribute to differences in observed compound potency in this format. Although this is an important benefit of the assay-the ability to differentiate compound interaction with different activation states of a kinase-it could potentially complicate comparisons of inhibitor potency between different assay formats. For example, an activity assay using a preparation of kinase that contains 10% active kinase and 90% nonactive kinase would be expected to report an inhibitor IC 50 value that was reflective of compound interaction with the active form of the kinase, whereas a kinase binding assay would report a value that was more heavily influenced by the presence of nonactivated kinase (assuming that the tracer still bound to the nonactivated form of the kinase). For these reasons, differences in compound action between this and other assay formats (particularly cell-based formats) should be investigated with this understanding in mind.
By designing tracers built on a small number of inhibitor scaffolds that bind to the ATP binding site of many kinases, we have used the strategy described here to develop robust (Z′ > 0.5), high-throughput compatible binding assays for more than 200 kinases spanning the kinome, including both active and nonactivated kinases, as well as many targets not previously amenable to HTS due to low activity or lack of a suitable substrate. 40 These 200 assays represent a success rate of >70% against all kinases with which the tracers have been tested and include members of all serine/threonine and tyrosine kinase subfamilies. In contrast to broadly targeted platforms based on the use of phage-displayed kinases, the method that we have developed can be applied to kinases in a more relevant context, such as in complex with relevant binding partners, and with appropriate effort, the exact phosphorylation state of the kinase can be controlled. In addition, we have demonstrated that the assay performs well in the presence of cellular lysates and expect that this will allow for additional applications of the technology in an even more physiologically relevant context. Although the work presented here focuses on protein kinases, and there is a dearth of broad-spectrum, high-potency lipid kinase inhibitors described in the literature upon which to base new tracers directed toward lipid kinase family members, we have recently extended this strategy to address mTOR (FRAP1) and p110α/ p85α (PIK3CA/PIK3R1) and thus expect the method to have utility outside of the protein kinase family.
